Objective To estimate the baseline risk of arrhythmic death required for prophylactic
implantable cardiac defibrillators (ICDs) to result in clinically meaningful survival benefits in …

Patients with left ventricular dysfunction are prone to sudden cardiac death, presumably from
ventricular tachyarrhythmias. Randomized controlled trials (RCTs) demonstrated that …

Background Eight randomized trials have evaluated whether the prophylactic use of an
implantable cardioverter–defibrillator (ICD) improves survival among patients who are at risk …

This article has been corrected. The original version (PDF) is appended to this article as a
supplement. Background: Implantable cardioverter-defibrillators (ICDs) for the primary …

Aims To reduce sudden cardiac death, implantable cardioverter-defibrillators (ICDs) are
indicated in patients with ischaemic and non-ischaemic dilated cardiomyopathy and a left …

Patients with impaired left ventricular systolic function frequently die suddenly because of
arrhythmic and nonarrhythmic causes. Nine trials have evaluated the utility of implantable …

Background Implantable cardioverter-defibrillators (ICDs) have been shown in primary
prevention efficacy trials to reduce mortality in patients with ischemic heart disease and left …

Background: Sudden cardiac death is common in persons with cardiovascular disease.
Purpose: To assess the efficacy of implantable cardioverter defibrillators (ICDs) in persons at …

After publication of secondary prevention trials for sudden cardiac death in the mid 1990s,
evaluation of implantable cardioverter-defibrillator (ICD) therapy in the lower risk, primary …

In both ischemic and nonischemic heart disease the severity of left ventricular dysfunction
has emerged as the key determinant affecting the decision of which patient should receive …